New Delhi: The National Immunobiological Company (Nacimbio), part of Rostec state corporation, at BIOTECHMED conference signed an agreement on the transfer of technology for the production of ready-made dosage forms and active pharmaceutical substances with the Indian pharmaceutical company Mylan Laboratories, part of a global company Mylan NV (USA).
The framework of the license agreement includes the transfer of technology for production of both ready-made forms and active pharmaceutical substances for the creation of modern combined drugs for the treatment of HIV infection.
At “Biotechmed-2017” conference, Mr Sergei Chemezov, CEO, Rostec said that the Corporation’s activities are aimed at reducing dependence on imported medicines. At the same time, the corporation is ready for a technological partnership in the pharmaceutical industry. “We are developing our own drug production, jointly with well-known foreign pharmaceutical companies, who are ready to localize production of their products in Russia,” said Sergei Chemezov.
Russia’s Nacimbio holding company (part of Rostec State Corporation) signed an agreement on technology transfer with the Indian company, Mylan Laboratories at “Biotechmed-2017” conference.